[ Lyndra Inc. raises $23M in Series A ]

Lyndra Inc. has raised $23 million in Series A funding.

Founded in 2015, Lyndra Inc. ’s technology is the first ultra-long acting, sustained release oral dosage form. Lyndra’s system enables linear drug release of small molecules and peptides for 7 days or more from each orally administered capsule.

The company will utilize the capital raised to further the development of its lead candidate program and increase manufacturing capabilities.

Funding  Series A
Founded  2015
Country  USA
City  Cambridge, Massachusetts
Founder / CEO  Amy Schulman
Deal Size  $23M
Investors  Suffolk Equity Partners
 Partners HealthCare
 Healthlink Capital
 Yonghua Capital
 GF Securities
 Quark Venture
 Polaris Partners
Previous Investors  /

[adyen action=”checkout_button”]